BKT-140

Research use only, not for human use.

BKT-140 (TF-14016) is a 14-residue bio stable synthetic peptide; high-affinity CXCR4 antagonist(IC50=1 nM).

BKT-140 (TF-14016) is a 14-residue bio stable synthetic peptide; high-affinity CXCR4 antagonist(IC50=1 nM); inhibits CXCL12-mediated migration of human Jurkat cells and mouse splenocyte in a dose-dependent manner in vitro (IC50=0.65 and 0.54 nM, respectively); ameliorates severity in collagen-induced arthritis in mice.Blood Cancer Phase 2 Clinical.

Motixafortide (BKT140) displays selective toxicity toward AmL and MM cells. Treatment with Motixafortide (BKT140) can overcome IL-6 dependent proliferation and survival of ARH77 MM cells. Motixafortide (BKT140) specifically triggers CXCR4-dependent cell death in leukemia and MM cells. Motixafortide (BKT140) stimulates apoptotic cell death in leukemia and MM cells.

Subcutaneous injections of Motixafortide (BKT140) significantly reduces, in a dose-dependent manner, the growth of human acute myeloid leukemia and multiple myeloma xenografts. Tumors from animals treated with Motixafortide (BKT140) are smaller in size and weights, had larger necrotic areas and high apoptotic scores.

BL-8040 | TF-14016 | 4F-Benzoyl-TN14003

GPCR/G Protein

Chemokine Receptor

Chemokine Receptor

Cancer

Blood cancer

664334-36-5

2159.52

C97H144FN33O19S2

>98% (HPLC)

DMSO: ≥ 36 mg/mL

C1CC2C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2C1)CCCCN)CCCCN)CCCNC(=O)N)CC3=CC=C(C=C3)O)NC(=O)C(CC4=CC5=CC=CC=C5C=C4)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C6=CC=C(C=C6)F)C(=O)NC(CCCNC(=N)N)C(=O)N)CCCNC(=O)N)CCCNC(=N)N)CC7=CC=C(C=C7)O

L-Argininamide, N2-(4-fluorobenzoyl)-L-arginyl-L-arginyl-3-(2-naphthalenyl)-L-alanyl-L-cysteinyl-L-tyrosyl-N5-(aminocarbonyl)-L-ornithyl-L-lysyl-D-lysyl-L-prolyl-L-tyrosyl-L-arginyl-N5-(aminocarbonyl)-L-ornithyl-L-cysteinyl-, cyclic (4→13)-disulfide

(-20℃)

With Ice Pack

≥ 2 years